| everolimus / Generic mfg. |
NCT01048723: Study of RAD001 in Soft Tissue Extremity and/or Retroperitoneal Sarcomas |
|
|
| Terminated | 2 | 2 | US | RAD001, everolimus | H. Lee Moffitt Cancer Center and Research Institute, Novartis | Sarcoma | 10/11 | 10/11 | | |
| Completed | 2 | 41 | RoW | RAD001, Everolimus | Asan Medical Center, Novartis | Soft Tissue Sarcomas, Bone Sarcomas | 01/13 | | | |
|
| Completed | 2 | 71 | Europe | Everolimus, RAD001 | Novartis Pharmaceuticals | Progressive Sarcoma | 05/17 | 05/17 | | |
NCT01661283: SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors |
|
|
| Completed | 2 | 25 | US | everolimus, Afinitor, everolimus, bevacizumab, Avastin | Sarcoma Alliance for Research through Collaboration, Novartis Pharmaceuticals, Genentech, Inc., United States Department of Defense | Malignant Peripheral Nerve Sheath Tumors, MPNST, Sarcoma | 06/17 | 12/17 | | |
|
2018-004623-36: MEGALiT - a study in which the effect of established cancer drugs is investigated on new cancers that have a specific molecular signature MEGALiT - en studie där effekten av etablerade cancerläkemedel undersöks på nya cancersjukdomar som har en specifik molekylär signatur |
|
|
| Not yet recruiting | 2 | 154 | Europe | Tecentriq, Cotellic, Zejula, Everolimus, RO5514041/F04, Concentrate for solution for infusion, Film-coated tablet, Capsule, hard, Tablet, Tecentriq, Cotellic, Zejula | Uppsala University Hospital, Roche AB | In part 1 of the study: any solid tumor with the exemption of sarcoma. In part 2: any solid tumor or hematological malignancy, In part 1 of the study: any solid tumor with the exemption of sarcoma. In part 2: any solid tumor or hematological malignancy, Diseases [C] - Cancer [C04] | | | | |
NCT01275222: Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors |
|
|
| Completed | 1/2 | 117 | Europe, US | RAD001, everolimus, Imatinib 600mg/day (Glevec is the brand name for imatinib), STI571, Imatinib 800mg/day (Glevec is the brand name for imatinib) | Novartis Pharmaceuticals | Gastrointestinal Stromal Tumors | 09/08 | 09/08 | | |
NCT03245151 / 2022-003736-77: Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors |
|
|
| Completed | 1/2 | 64 | Canada, US | Lenvatinib, Everolimus | Eisai Inc., Merck Sharp & Dohme LLC | Recurrent and Refractory Solid Tumors | 09/22 | 09/22 | | |
